Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of “Buy” from Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned a consensus recommendation of “Buy” from the eight research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $8.80.

Several research analysts have recently commented on AQST shares. Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Finally, Lake Street Capital set a $6.00 price target on Aquestive Therapeutics in a research note on Tuesday, February 3rd.

More Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright issued a more favorable near‑term earnings outlook and raised some FY estimates, offering modest analytical support if operational/regulatory progress continues. HC Wainwright Estimates
• Neutral Sentiment: Coverage pieces (market commentary) explain recent volatility and provide context for regulatory risk tied to Anaphylm; these explain price moves but do not change fundamentals immediately. AAII: Why AQST Is Down
• Neutral Sentiment: Short‑interest figures circulating this week show anomalous zero/NaN values (likely reporting error) and should not be used to support a short‑squeeze thesis until official confirmations are posted. (No authoritative link provided.)
• Negative Sentiment: Multiple law firms have filed or advertised class actions for purchasers between June 16, 2025 and Jan 8, 2026; several solicitations for lead‑plaintiff roles raise the prospect of material litigation costs, management distraction, and downside risk to the stock. Rosen Law Firm Notice
• Negative Sentiment: Additional class‑action notices from other firms (Pomerantz, Faruqi, Bernstein, Portnoy) amplify the legal narrative and extend the timeline of investor uncertainty. Pomerantz Alert
• Negative Sentiment: Insider selling: a disclosed sale (15,741 shares by Sherry Korczynski and other senior officer transactions) at roughly $4.17 reduces insider holdings and is often interpreted negatively by the market. InsiderTrades: Insider Sale
• Negative Sentiment: A PR Newswire item highlights an allegation tied to an analyst’s large price‑target cut (Cantor), linking that cut to a sharp one‑day selloff; this adds to reputational/regulatory narrative around prior communications and approval risk for Anaphylm. PR Newswire: Analyst Lawsuit

Aquestive Therapeutics Stock Performance

Shares of Aquestive Therapeutics stock opened at $4.02 on Monday. Aquestive Therapeutics has a 52-week low of $2.12 and a 52-week high of $7.55. The stock has a market capitalization of $490.60 million, a price-to-earnings ratio of -5.15 and a beta of 1.61. The company has a fifty day moving average of $3.99 and a 200-day moving average of $5.22.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The company had revenue of $13.02 million for the quarter, compared to the consensus estimate of $13.28 million. On average, equities research analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In related news, CFO A Ernest Toth, Jr. sold 58,254 shares of Aquestive Therapeutics stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total value of $242,919.18. Following the transaction, the chief financial officer directly owned 376,112 shares of the company’s stock, valued at $1,568,387.04. The trade was a 13.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Lori J. Braender sold 40,102 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $4.17, for a total transaction of $167,225.34. Following the sale, the insider directly owned 442,879 shares of the company’s stock, valued at $1,846,805.43. The trade was a 8.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 395,690 shares of company stock valued at $1,650,027. 7.85% of the stock is currently owned by insiders.

Institutional Trading of Aquestive Therapeutics

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Aquestive Therapeutics by 30.8% in the third quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company’s stock worth $31,651,000 after purchasing an additional 1,333,627 shares during the last quarter. Federated Hermes Inc. raised its position in Aquestive Therapeutics by 159.4% during the 4th quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company’s stock valued at $13,132,000 after purchasing an additional 1,249,044 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Aquestive Therapeutics by 6,233.4% in the 4th quarter. BNP Paribas Financial Markets now owns 1,171,675 shares of the company’s stock worth $7,569,000 after buying an additional 1,153,175 shares during the period. Commonwealth Equity Services LLC purchased a new stake in Aquestive Therapeutics in the 3rd quarter worth approximately $5,918,000. Finally, Wells Fargo & Company MN grew its position in shares of Aquestive Therapeutics by 804.6% in the 4th quarter. Wells Fargo & Company MN now owns 1,188,531 shares of the company’s stock worth $7,678,000 after buying an additional 1,057,145 shares during the last quarter. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.